Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828263 | 0.92 | POLG (0.52) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL15828309 | 0.92 | POLG (0.52) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18877180 | 0.90 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL18672091 | 0.89 | POLG (0.51) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17860802 | 0.88 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL16368127 | 0.88 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL17861897 | 0.88 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL15070741 | 0.88 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL16490106 | 0.88 | POLG (0.49) | POLGP2RY2P2RY4P2RY6POLB | |
| SCHEMBL15074336 | 0.88 | POLG (0.53) | POLGP2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-23 | — | — | US | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2014165542-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | POLG 1235/4885P2RY2 133/4885P2RY4 43/4885 |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | POLG 496/4885P2RY2 837/4885P2RY4 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.